主页 > 生命科学 >
【medical-news】蛇毒展示了对抗严重神经痛的新途
Snail Toxins Reveal Novel Way To Fight Severe Nerve Pain
A brand new approach to treating severe nerve pain - by aiming drugs at a previously unrecognized molecular target - has been discovered by University of Utah scientists who study the venoms of deadly, sea-dwelling cone snails.
"We found a new way to treat a chronic and debilitating form of pain suffered by hundreds of millions of people on Earth," says J. Michael McIntosh, a University of Utah research professor of biology, and research director and professor in the Department of Psychiatry. "It is a previously unrecognized mechanism for treating pain."
The findings are being published the week of Nov. 13 in the online edition of the journal Proceedings of the National Academy of Sciences.
The study in rats found that cone snail toxins named RgIA and Vc1.1 can treat nerve hypersensitivity and pain by blocking a molecule in cells known as the "alpha9alpha10 nicotinic acetylcholine receptor."
"The numerous analgesic compounds currently available are largely ineffective" for chronic nerve pain, McIntosh and colleagues write. "Our findings not only suggest a previously unrecognized molecular mechanism for the treatment of neuropathic pain, but also demonstrate the involvement of alpha9alpha10 nicotinic receptors" in nerve injury.
McIntosh emphasized neither substance will be on the market soon. Vc1.1, also known as ACV1, is being developed by an Australian company, Metabolic, and is undergoing trials of its effectiveness in human patients. While Metabolic has said the drug targets nicotinic receptors, McIntosh says alpha9alpha10 nicotinic receptors have not been reported previously as a target for any kind of painkilling medication. McIntosh says Vc1.1 is administered by subcutaneous (under the skin) injection.
McIntosh hopes the new findings make it feasible to develop a painkiller based on RgIA that could be taken orally, but he believes that will take at least 10 years. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Snail Toxins Reveal Novel Way To Fight Severe Nerve Pain
A brand new approach to treating severe nerve pain - by aiming drugs at a previously unrecognized molecular target - has been discovered by University of Utah scientists who study the venoms of deadly, sea-dwelling cone snails.
从事海洋芋螺剧毒毒液研究的美国犹他州大学的科学家发现，芋螺毒素可通过以往未知的分子靶点，治疗严重的神经疼痛。
"We found a new way to treat a chronic and debilitating form of pain suffered by hundreds of millions of people on Earth," says J. Michael McIntosh, a University of Utah research professor of biology, and research director and professor in the Department of Psychiatry. "It is a previously unrecognized mechanism for treating pain."
美国犹他州大学生物学研究员、精神病学教授说：“我们发现了治疗全世界成百上千万慢性疼痛患者新的治理方法，作用机制与以往不同”
The findings are being published the week of Nov. 13 in the online edition of the journal Proceedings of the National Academy of Sciences.
该发现登载在11月13日美国国家科学院学报网络版上。
The study in rats found that cone snail toxins named RgIA and Vc1.1 can treat nerve hypersensitivity and pain by blocking a molecule in cells known as the "alpha9alpha10 nicotinic acetylcholine receptor."
在大鼠身上的研究发现，被命名为RgIA 、 Vc1.1芋螺毒素，可阻断细胞上a9a10烟碱样受体，治疗神经性超敏和神经性疼痛。
"The numerous analgesic compounds currently available are largely ineffective" for chronic nerve pain, McIntosh and colleagues write. "Our findings not only suggest a previously unrecognized molecular mechanism for the treatment of neuropathic pain, but also demonstrate the involvement of alpha9alpha10 nicotinic receptors" in nerve injury.
McIntosh及其同事们认为：对于慢性疼痛，目前使用的许多止痛剂大多没有效果，该研究提示治疗神经病理性疼痛涉及以往没有认识的分子机制，同时也证明了神经损伤与a9a10烟碱样乙酰胆碱受体有关。
McIntosh emphasized neither substance will be on the market soon. Vc1.1, also known as ACV1, is being developed by an Australian company, Metabolic, and is undergoing trials of its effectiveness in human patients. While Metabolic has said the drug targets nicotinic receptors, McIntosh says alpha9alpha10 nicotinic receptors have not been reported previously as a target for any kind of painkilling medication. McIntosh says Vc1.1 is administered by subcutaneous (under the skin) injection.
McIntosh强调：RgIA 、 Vc1.1最近不可能上市。澳大利亚一家Metabolic公司正在开发Vc1.1（也称ACV1），目前对所有的疼痛正在进行试验。Metabolic公司认为，该药作用于烟碱样受体，Vc1.1说a9a10烟碱样乙酰胆碱受体作为止痛剂的靶点以往没有报道过。Vc1.1是通过皮下注射的。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-22 02:35
医学,生命科学网